Compare ADMA Biologics Inc (ADMA) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Anheuser-Busch Inbev SA — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Anheuser-Busch Inbev SA trades at $79.4 (market cap $155.34B). The key difference: Anheuser-Busch Inbev SA is far larger — about 72.9× ADMA Biologics Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.69% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BUD | |
|---|---|---|
Market Cap | $2.13B | $155.34B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $85.09 |
52-Week Low | $7.60 | $57.10 |
Enterprise Value | $2.20B | $216.53B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BUD trades at $79.74, down 1.95% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, maintains healthy profit margins (net income margin 11.9%), and shows improving cash flow trends. Recent news highlights premiumization strategies and digital expansion efforts to drive growth amid changing consumer preferences in the beverage-alcohol industry.
The outlook remains positive with analyst consensus pointing to 13% upside to the $90.08 price target. Key opportunities include continued earnings momentum and dividend yield support, while risks involve alcohol consumption trends and competitive pressures. The stock presents a compelling value proposition for investors seeking stable returns with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
